Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
American Airlines Group Inc. stock logo
AAL
American Airlines Group
$9.90
+0.5%
$11.34
$8.50
$19.10
$6.53B1.1738.87 million shs60.75 million shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$49.21
+1.5%
$56.24
$39.35
$63.33
$100.13B0.4112.96 million shs19.79 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
American Airlines Group Inc. stock logo
AAL
American Airlines Group
+1.03%+8.60%-7.94%-42.57%-29.03%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
+1.23%-1.02%-19.38%-17.67%+8.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
American Airlines Group Inc. stock logo
AAL
American Airlines Group
4.7892 of 5 stars
4.32.01.70.02.90.84.4
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.5627 of 5 stars
3.23.04.24.02.63.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
American Airlines Group Inc. stock logo
AAL
American Airlines Group
2.65
Moderate Buy$16.2564.09% Upside
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.32
Hold$58.0017.86% Upside

Current Analyst Ratings Breakdown

Latest AAL and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2025
American Airlines Group Inc. stock logo
AAL
American Airlines Group
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $14.00
4/25/2025
American Airlines Group Inc. stock logo
AAL
American Airlines Group
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnchanged$13.00
4/25/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/25/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/23/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$70.00 ➝ $68.00
4/22/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$55.00 ➝ $55.00
4/22/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00
4/11/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$60.00 ➝ $54.00
4/8/2025
American Airlines Group Inc. stock logo
AAL
American Airlines Group
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $11.00
4/8/2025
American Airlines Group Inc. stock logo
AAL
American Airlines Group
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Sell$16.00 ➝ $8.00
4/8/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$67.00 ➝ $55.00
(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
American Airlines Group Inc. stock logo
AAL
American Airlines Group
$54.21B0.12$3.57 per share2.77($6.05) per share-1.64
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$47.64B2.10$5.19 per share9.48$8.08 per share6.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
American Airlines Group Inc. stock logo
AAL
American Airlines Group
$846M$1.148.683.130.211.56%-28.56%2.15%N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$8.95B$2.67N/A8.082.07-18.53%13.93%2.46%N/A

Latest AAL and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025Q1 2025
American Airlines Group Inc. stock logo
AAL
American Airlines Group
-$0.69-$0.59+$0.10-$0.72$12.71 billion$12.55 billion
4/24/2025Q1 2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.50$1.80+$0.30$1.21$10.77 billion$11.20 billion
2/6/2025Q4 2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.47$1.67+$0.20$0.04$11.57 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
American Airlines Group Inc. stock logo
AAL
American Airlines Group
$0.404.04%N/A35.09%N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.485.04%+6.38%92.88%17 Years

Latest AAL and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/3/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.624.14%4/4/20254/4/20255/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
American Airlines Group Inc. stock logo
AAL
American Airlines Group
N/A
0.54
0.43
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.90
1.25
1.15

Institutional Ownership

CompanyInstitutional Ownership
American Airlines Group Inc. stock logo
AAL
American Airlines Group
52.44%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%

Insider Ownership

CompanyInsider Ownership
American Airlines Group Inc. stock logo
AAL
American Airlines Group
0.49%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
American Airlines Group Inc. stock logo
AAL
American Airlines Group
129,700659.51 million654.35 millionOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,3002.03 billion2.03 billionOptionable

Recent News About These Companies

Should You BMY Stock At $48?
William Blair Brokers Reduce Earnings Estimates for BMY
Bristol-Myers Squibb stock logo
William Blair Issues Pessimistic Outlook for BMY Earnings
Q2 EPS Estimate for Bristol-Myers Squibb Reduced by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
American Airlines Group stock logo

American Airlines Group NASDAQ:AAL

$9.90 +0.05 (+0.51%)
Closing price 04:00 PM Eastern
Extended Trading
$9.88 -0.03 (-0.25%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

American Airlines Group Inc., through its subsidiaries, operates as a network air carrier. The company provides scheduled air transportation services for passengers and cargo through its hubs in Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C., as well as through partner gateways in London, Doha, Madrid, Seattle/Tacoma, Sydney, and Tokyo. It operates a mainline fleet of 965 aircraft. The company was formerly known as AMR Corporation and changed its name to American Airlines Group Inc. in December 2013. American Airlines Group Inc. was founded in 1926 and is headquartered in Fort Worth, Texas.

Bristol-Myers Squibb stock logo

Bristol-Myers Squibb NYSE:BMY

$49.21 +0.75 (+1.55%)
Closing price 03:59 PM Eastern
Extended Trading
$49.38 +0.16 (+0.34%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.